Martina Kluibenschaedl
Overview
Explore the profile of Martina Kluibenschaedl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kliess M, Kluibenschaedl M, Zoehrer R, Schlick B, Scandurra F, Urban M
Value Health
. 2017 Oct;
20(8):1092-1099.
PMID: 28964441
Background: Partially implantable active middle ear implants (aMEIs) offer a solution for individuals who have mild to severe sensorineural hearing loss and an outer ear medical condition that precludes the...
2.
Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, et al.
Leuk Res Treatment
. 2016 Jan;
2015:982395.
PMID: 26783469
Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and...
3.
Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, et al.
Leuk Lymphoma
. 2014 Nov;
56(8):2315-25.
PMID: 25393806
Several tyrosine kinase inhibitors (TKIs) are approved for chronic myeloid leukemia (CML) therapy. We evaluated the long-term cost-effectiveness of seven sequential therapy regimens for CML in Austria. A cost-effectiveness analysis...
4.
Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, et al.
Appl Health Econ Health Policy
. 2014 Jan;
12(2):103-15.
PMID: 24385259
Background: Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of chronic myeloid leukemia (CML). Decision-analytic modeling can help to extrapolate data from short-term clinical trials and also consider...